Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database
<b>Background/Objectives</b>: The recent approval of the first intranasal calcitonin gene-related peptide receptor antagonist (CGRP-RA), zavegepant, has increased the relevance of this drug class in treating acute migraine. However, introducing an alternative delivery method may result in a differen...
Zapisane w:
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2026-06-01
|
| Seria: | Pharmaceuticals |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/1424-8247/19/6/943 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|